Skip to main content

Table 1 Baseline comparisons between responder groups and training/test sets. Baseline demographic and clinical characteristics were compared (a) between the good and poor responders defined using latent class mixed modeling and (b) between the unimputed training and test sets

From: Clinical predictors of response to methotrexate in patients with rheumatoid arthritis: a machine learning approach using clinical trial data

 

Responder group comparisons

Training/test set comparisons

Total

(n = 775)

Good responders (n = 510)

Poor responders (n = 265)

p-value*

Training set (n = 365)

Test set (n = 410)

p-value*

Age, years

50 (40, 58) (n = 371)

50 (41, 57) (n = 237)

0.66

50 (40, 57)

50 (40, 59) (n = 243)

0.40

50 (40, 58) (n = 608)

Female, n (%)

402 (78.8)

215 (81.1)

0.45

286 (78.4)

331 (80.7)

0.41

617 (79.6)

Race: White, n (%)

269 (52.7)

157 (59.2)

0.08

239 (65.5)

187 (45.6)

 < 0.001

426 (55)

DAS28-ESR

6.5 (5.9, 7.2)

7.6 (6.9, 8.1)

 < 0.001

7.1 (6.4, 7.8)

6.7 (6.0, 7.4)

 < 0.001

6.9 (6.2, 7.6)

TJC28

14 (9, 20)

21 (16, 26)

 < 0.001

18 (12, 24)

15 (10, 22)

 < 0.001

16 (11, 23)

SJC28

10.5 (7, 15)

15 (11, 22)

 < 0.001

13 (9, 19)

11 (8, 16)

 < 0.001

12 (8, 17)

ESR, mm/h

42.5 (31, 64)

63 (42, 88)

 < 0.001

57 (38, 81)

42.5 (32, 64)

 < 0.001

49 (34, 74.5)

PtGA

65 (50, 79)

76 (61, 88)

 < 0.001

71 (55, 83)

67 (50, 82)

 < 0.001

69 (52, 83)

CRP, mg/L

2.3 (0.9, 5.0) (n = 509)

3.1 (1.4, 7.2) (n = 263)

 < 0.001

2.4 (1.3, 4.4) (n = 362)

2.7 (0.8, 8.9)

0.25

2.5 (1.0, 6.2) (n = 772)

PhGA

66 (52, 76) (n = 509)

72 (62, 83)

 < 0.001

70 (56, 80) (n = 364)

68 (53.2, 77)

0.034

68.5 (55, 78) (n = 774)

RF positive, n (%)

463 (91.1) (n = 508)

241 (90.9)

0.93

329 (90.1)

375 (91.9) (n = 408)

0.39

704 (91.1) (n = 773)

ACPA positive, n (%)

447 (88.3) (n = 506)

230 (87.8) (n = 262)

0.82

325 (90.3) (n = 360)

352 (86.3) (n = 408)

0.09

677 (88.2) (n = 768)

Glucocorticoids use, n (%)

124 (46.4) (n = 267)

56 (36.4) (n = 154)

0.044

87 (48.9) (n = 178)

93 (38.3) (n = 243)

0.030

180 (42.8) (n = 421)

HAQ

1.6 (1.1, 2.0) (n = 463)

2.0 (1.6, 2.4) (n = 238)

 < 0.001

2.0 (1.6, 2.2) (n = 294)

1.6 (1.1, 2.0) (n = 407)

 < 0.001

1.8 (1.2, 2.1) (n = 701)

RA duration, months

3.7 (1.5, 7.9)

5.3 (2.2, 13.4)

 < 0.001

6.9 (3.6, 17.2)

2.2 (1.0, 5.7)

 < 0.001

4.1 (1.7, 9.2)

Good Responders, n (%)

   

199 (54.5)

311 (75.9)

 < 0.001

 
  1. Median (interquartile range) are reported unless noted otherwise
  2. Abbreviations: ACPA, anti-citrullinated protein antibody, CRP, C-reactive protein, DAS28-ESR, disease activity score including 28-joint counts and ESR, erythrocyte-sedimentation rate, HAQ, Health Assessment Questionnaire, PtGA, Patient’s Global Assessment of Disease Activity, PhGA, Physician’s Global Assessment of Disease Activity, RA, rheumatoid arthritis, RF, rheumatoid factor, SJC28, swollen joint count, TJC28, 28-tender joint count
  3. *p-values are reported from the Kruskal–Wallis rank sum test for continuous data and Pearson’s chi-squared test for categorical data
Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us